Jounce Therapeutics Inc (NASDAQ:JNCE) shares shot up 5.4% during mid-day trading on Thursday . The stock traded as high as $4.61 and last traded at $4.49, 159,012 shares changed hands during trading. A decline of 15% from the average session volume of 187,474 shares. The stock had previously closed at $4.26.
The company has a debt-to-equity ratio of 0.20, a quick ratio of 2.24 and a current ratio of 2.24. The stock has a market capitalization of $138.32 million, a price-to-earnings ratio of -5.35 and a beta of 3.46. The company’s 50 day simple moving average is $4.66.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.07). Jounce Therapeutics had a negative net margin of 41.13% and a negative return on equity of 26.05%. The firm had revenue of $10.98 million for the quarter, compared to analyst estimates of $14.75 million. Research analysts predict that Jounce Therapeutics Inc will post -1.2 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the company. Algert Global LLC acquired a new position in shares of Jounce Therapeutics during the first quarter valued at $88,000. Bailard Inc. acquired a new position in Jounce Therapeutics in the first quarter valued at about $92,000. SG Americas Securities LLC acquired a new position in Jounce Therapeutics in the fourth quarter valued at about $55,000. Paloma Partners Management Co acquired a new position in Jounce Therapeutics in the fourth quarter valued at about $59,000. Finally, Rhumbline Advisers lifted its stake in Jounce Therapeutics by 39.4% in the fourth quarter. Rhumbline Advisers now owns 19,151 shares of the company’s stock valued at $65,000 after buying an additional 5,410 shares during the period. 73.29% of the stock is currently owned by institutional investors and hedge funds.
About Jounce Therapeutics (NASDAQ:JNCE)
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Recommended Story: Consumer behavior in bull markets
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.